Results 91 to 100 of about 5,933 (115)

Ocrelizumab-induced acute pancreatitis: case report of an uncommon side effect of multiple sclerosis treatment. [PDF]

Int J Surg Case Rep
Hanna S, Selvendran S.
europepmc   +1 more source

Combining Pembrolizumab and Ofatumumab in Triple-Negative Breast Cancer and Multiple Sclerosis: A Case Report. [PDF]

Surg Case Rep
Iriyama H, Iwase M, Takano Y, Takeuchi D, Ichikawa T, Ohata R, Ozaki Y, Yamamoto M, Inaguma G, Torii N, Toyoda C, Kawabe K, Kikumori T, Masuda N.   +13 more
europepmc   +1 more source

Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab. [PDF]

Mult Scler
MacMillan EL, Russell-Schulz B, Alejo G, Harp C, Cameron B, Winger R, Jia S, Herman A, Kassam J, Waine M, Vavasour IM, Cross H, Tam R, Traboulsee AL, Carruthers R, Kolind SH.   +15 more
europepmc   +1 more source

CD56^brightNK cells are negatively associated with antibody response to vaccination in people with multiple sclerosis on B-cell-depleting therapy. [PDF]

Clin Transl Immunology
Perkins GB, Hope CM, Chai CS, Tunbridge MJ, Sterling S, Webb K, Yap J, Yeow AEL, Masavuli MG, Scaffidi J, Zuiani JD, Akerman A, Aggarwal A, Milogiannakis V, Roberts MB, Hurtado PR, Turville S, Grubor-Bauk B, Barry SC, Ravindran J, Coates PT, Hissaria P.   +21 more
europepmc   +1 more source

Short-term effects of ocrelizumab on cortical pathology in patients with multiple sclerosis. [PDF]

Neurotherapeutics
Cavalli N, Boffa G, Cipriano E, Boccia VD, Al Qudsi S, Baldisseri F, Leveraro E, Nasone L, Magon S, Cellerino M, Inglese M, Lapucci C.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness

Multiple Sclerosis and Related Disorders, 2021
Antonija Babić, Magdalena Krbot Skoric, Mario Habek   +2 more
exaly  

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population

Journal of Drug Assessment, 2021
Rajvir Singh, Dirk Deleu, Gowrii Saswathy Ganesan   +2 more
exaly  

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic

Multiple Sclerosis Journal, 2022
Charlotte Teunissen, Joep Killestein, Alyssa A Toorop   +2 more
exaly  

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study

Journal of Neurology, 2022
Guido Ahle, Nicolas Collongues, Kévin Bigaut   +2 more
exaly